My multidisciplinary glycobiology group focuses on developing novel solutions for hard-to-diagnose and treat diseases such as triple-negative breast cancer and endometriosis through abnormal carbohydrate (glycan) structures and altered redox conditions. We generate and engineer several nanobody-based tools against human and bacterial glycans and continue to develop our patented CysCAR-T technology.